Fluorodeoxyglucose

Phase 3Radiopharmaceutical

SStanford University

Fluorodeoxyglucose is one of 10 small molecule programs targeting Histiocytosis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HistiocytosisActive, not recruiting

HistiocytosisPhase 3

Active, not recruiting

Competition

Competitive Landscape

11 competitors in Histiocytosis

#DrugCompanyPhaseTrials

Jakafi

Incyte

Approved

3 2

Vepesid

AAvyxa

Approved

8 3

Decadron

AAspen Global Incorporated

Approved

6 4

Alkeran

Leustatin

Mekinist

1 7

Zelboraf

CConrado Roberto Hoffmann Filho

Phase 2

1 8

Fluorodeoxyglucose

SStanford University

Phase 3

1 9

Prevymis

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 10

EBV-TCR-T Cells

FFujian Cancer Hospital

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Active, not recruiting

Early Onset Alzheimer Disease

NCT03507257

Q2 2027

Phase 3Active, not recruiting

Histiocytosis

NCT04943211

Clinical

Trials by Indication[1]

PET/CT1 trial

Optimizing Acquisition Parameters and Interpretive Methods of FDG-PET/CT With Rb-82

Completed·YYale University·Phase 1·NCT03048097·15 enrolled

Esophageal Cancer1 trial

Phase I Dose Escalation of Stereotactic Radiosurgical Boost for Locally Advanced Esophageal Cancer

Terminated·SStanford University·Phase 1·NCT00368329·4 enrolled

Lymphoma1 trial

[68Ga]Ga-PentixaFor-PET Imaging for Staging of Marginal Zone Lymphoma

Terminated·PPentixapharm AG·Phase 3·NCT06125028·13 enrolled

Histiocytosis1 trial

Determination of Molecular Status, as Well as the Efficacy and Safety of Fluorodeoxyglucose (18F-FDG) in PET-CT Imaging in Juvenile Patients With Histiocytosis

Active, not recruiting·AAnna Raciborska·Phase 3·NCT04943211·150 enrolled

Early Onset Alzheimer Disease1 trial

Longitudinal Early-onset Alzheimer's Disease Study Protocol

Active, not recruiting·IIndiana University··NCT03507257·850 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Fluorodeoxyglucose. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fluorodeoxyglucose compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fluorodeoxyglucose. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Stanford University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Radiopharmaceutical[2]
Highest Phase: Phase 3[1]
Company: SStanford University

Fluorodeoxyglucose

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2027

Trials by Indication[1]

PET/CT1 trial

Esophageal Cancer1 trial

Lymphoma1 trial

Histiocytosis1 trial

Early Onset Alzheimer Disease1 trial

References

Drug Info

Quick Facts

Related News